ABC

Johnson & Johnson’s Pending Split-Up, Talc Liabilities, New CEO Add Complexity to a Once-Clean Dividend Growth Story

by

  Image Shown: J&J continues to face legal liabilities due to talcum powder lawsuits. Image Source: Mike Mozart.  By Brian Nelson, CFA Johnson & Johnson’s (JNJ) dividend growth story has become much more complicated in recent years. On a price-only basis, shares of the consumer and pharma giant haven’t been nearly as impressive as that of technology names, but the company still has put up a nice 45% price-only return the past five years, further bolstered by a continuous stream of quarterly dividend payments. J&J yields ~2.6% at the time of this writing, and the company reluctantly remains the bedrock of the Dividend Growth Newsletter portfolio, at least for now. The Split-Up Before we dig into J&J’s fourth-quarter 2021 results, … Read more

Don’t Throw the Baby Out with the Bathwater

by

Image: Erica Nicol Takeaways: Junk tech should continue to collapse, but the stylistic area of large cap growth and big cap tech should remain resilient. Moderately elevated levels of inflation coupled with interest rates hovering at all-time lows isn’t a terrible combination. In fact, it’s not bad at all. The markets are digesting the huge gains of the past few years so far in 2022, and the excesses in ARKK funds, crypto, SPACs, and meme stocks are being rid from the system. Our best ideas are “outperforming” the very benchmarks that are outperforming everyone else. The BIN portfolio is down 6.4% and the DGN portfolio is down 3.2% year to date. The SPY is down 7.8%, while the average investor … Read more

Dividend Growth Idea UnitedHealth’s Growth Story Expected to Continue

by

Image Shown: Shares of dividend growth idea UnitedHealth Group Inc have surged higher over the past year. The company put up solid performance in 2021 and its guidance for 2022 indicates that its growth trajectory is expected to continue. By Callum Turcan On January 19, UnitedHealth Group Inc (UNH) reported fourth-quarter 2021 earnings that beat both consensus top- and bottom-line estimates. The company’s health insurance business is covered by its ‘UnitedHealthcare’ segment, and its health care provider business is covered by its ‘Optum’ segment. Virtually all of the firm’s revenues come from the U.S. It also reaffirmed its guidance for 2022 in its fourth-quarter earnings report. We continue to be impressed with UnitedHealth and include shares of UNH as an … Read more

Hard Work and the Trust That Binds

by

Image Source: Terry Johnson By Brian Nelson, CFA We’ll have our traditional Valuentum Weekly email coming out on Sunday, and I’m excited to say our team is putting the finishing touches on our technology industry update, so we’ll have a whole bunch of fresh reports for you to look at Sunday evening/Monday morning. It’s easy to forget how much we’ve been through the past two years. Often, we forget how helpful the warning that markets were going to crash was the weekend before they did on February 22, 2020, “Is a Stock Market Crash Coming? – Coronavirus Update and P/E Ratios,” how we thought dollar-cost-averaging made sense at the bottom in March 2020, and how we went “all-in” in April … Read more

Johnson & Johnson Boosts Guidance Again, Posts Great Earnings Update

by

Image Shown: Johnson & Johnson reported strong performance across its three core business operating segments in the third quarter of fiscal 2021. Image Source: Johnson & Johnson – Third Quarter of Fiscal 2021 IR Earnings Presentation By Callum Turcan On October 19, Johnson & Johnson (JNJ) reported third quarter earnings for fiscal 2021 (period ended around the end of September 2021) that missed consensus top-line estimates but beat consensus bottom-line estimates. The healthcare giant also raised its full-year guidance (again) for fiscal 2021 as its ‘Pharmaceutical’ segment is growing at a robust pace, its ‘Medical Device’ segment is steadily recovering from the worst of the coronavirus (‘COVID-19’) pandemic, and its ‘Consumer Health’ segment is holding up well. We continue to … Read more

Dividend Growth Idea UnitedHealth Group Beats Estimates, Raises Guidance (Again)

by

Image Shown: Shares of dividend growth idea UnitedHealth Group Inc moved higher in the wake of its latest earnings report and guidance boost. By Callum Turcan On October 14, the health insurance and health care services provider giant UnitedHealth Group Inc (UNH) reported third-quarter 2021 earnings that beat both consensus top- and bottom-line estimates. The company also raised its full-year earnings guidance (again) for 2021 in conjunction with its latest earnings report, boosting its EPS forecast to $17.70-$17.95 and its non-GAAP adjusted EPS forecast to $18.65-$18.90. Please note that UnitedHealth Group also increased its full-year earnings guidance during the first and second quarters of 2021. Back in December 2020, UnitedHealth Group expected to post $16.90-$17.40 in EPS and $17.75-$18.25 in … Read more

Dividend Growth Idea UnitedHealth Group Surges Towards All-Time Highs After Stellar Earnings Update, Guidance Boost

by

Image Shown: Shares of UnitedHealth Group Inc, an idea in the Dividend Growth Newsletter portfolio, are trading near their all-time highs as of this writing after the firm reported a stellar second quarter 2021 earnings report. In conjunction with its latest earnings report, UnitedHealth Group once again raised its full-year adjusted EPS guidance for 2021. We continue to be huge fans of the name. By Callum Turcan On July 15, UnitedHealth Group Inc (UNH) reported second-quarter 2021 earnings that beat both consensus top- and bottom-line estimates thanks to the enduring strength of its Optum businesses and strong performance at its UnitedHealthcare health insurance businesses. Its Optum businesses provide an expansive slate of healthcare offerings from ambulatory services to pharmacy and … Read more

Dividend Growth Idea UnitedHealth Group Boosts Payout

by

Image Shown: We include UnitedHealth Group Inc as an idea in our Dividend Growth Newsletter portfolio. The health care giant recently boosted its quarterly payout by 16% on a sequential basis. By Callum Turcan Recently, the US-based health care insurance, services, and solutions provider UnitedHealth Group Inc (UNH) boosted its quarterly dividend by 16% to $1.45 per share or $5.80 on an annualized basis. On a forward-looking basis, shares of UNH yield ~1.5% as of this writing. We include UnitedHealth Group as an idea in the Dividend Growth Newsletter portfolio as its forward-looking dividend coverage is rock-solid. Strong Payout Coverage UnitedHealth Group’s Dividend Cushion ratio sits at 3.1, which incorporates our expectations the firm will significantly grow its payout in … Read more

ICYMI — Video: Exclusive 2020 — Furthering the Financial Discipline

by

ICYMI — Video: Exclusive 2020 — Furthering the Financial Discipline — — In this 40+ minute video jam-packed with must-watch content, Valuentum’s President Brian Nelson talks about the Theory of Universal Valuation and how his work is furthering the financial discipline. Learn the pitfalls of factor investing and modern portfolio theory and how the efficient markets hypothesis holds little substance in the wake of COVID-19. He’ll talk about which companies Valuentum likes and why, and which areas he’s avoiding. This and more in Valuentum’s 2020 Exclusive conference call.   Note: This video was originally published August 2, 2020.    To watch the video >>   The Theory of Universal Valuation —– Valuentum members have access to our 16-page stock reports, … Read more

One of Our Favorite Dividend Growth Ideas J&J Smashes Consensus Estimates

by

Image Shown: Summary of Johnson & Johnson’s first-quarter 2021 earnings results. Image Source: J&J. Valuentum’s Dividend Growth Newsletter portfolio >> By Callum Turcan On April 20, Johnson & Johnson (JNJ) reported first quarter 2021 earnings that smashed past consensus estimates. In conjunction with the solid earnings report, Johnson & Johnson raised its quarterly dividend 5% sequentially to $1.06 per share or $4.24 per share on an annualized basis, good for a forward-looking yield of ~2.5% as of this writing. The health care giant’s outperformance largely came from its ‘Medical Devices’ segment, which took a beating last year as the COVID-19 pandemic prompted widespread deferrals of elective surgeries. Last quarter, this part of the firm’s business grew its reported sales by … Read more